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26% when patients were rated as “improved,” and 45%,
50%, respectively when rated as “much better.” Mean
7-point item scores improved by 0.46 points PANSS,
0.23 points QLS for “improved” patients, and by 0.88,
0.92, respectively for “much better” patients. Minimal
changes were seen for all items when patients were rated
as “unchanged.” The relationship between clinician rat-
ings and score changes was stable over multiple assess-
ments in this large sample. CONCLUSION: These data
describe the amount of change that represents clinically
important improvement related to treatment based on
commonly used symptom and QOL scales. Planning
sample sizes for clinical trials can be based on percentage
change in scores or mean item scores to aid clinicians and
researchers in understanding meaningful treatment ef-
fects.
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OBJECTIVES: The MSQ (Migraine Specific Quality of
Life Questionnaire) measures migraine-related quality of
life in three dimensions [Role Restrictive (RR), Role Pre-
ventive (RP), and Emotional Function (EF)]. The objec-
tive of this analysis was to compare the psychometric
properties of the Finnish (FN), Dutch (HD), Hungarian
(HG), Spanish (SP), and UK English translations with the
original US English version of the MSQ. METHODS:
One hundred and ninety-eight Finns, 127 Dutch, 169
Hungarians, 116 New Zealanders, and 169 Spaniards,
participated in a multinational migraine clinical trial in
which the MSQ was completed at baseline and after a 3-
month treatment period with customary therapy or
naratriptan 2.5 mg. The distribution of item responses,
item-discriminant validity and scale-level reliability for
the MSQ translations were examined and compared to
the previously published US English version results. RE-
SULTS: The distribution of responses for each item was
negatively skewed for all translations. The full range of
the response categories was used by migraineurs from all
countries except for the FN version in the clinical trial.
Every translation of the MSQ possessed item-scale corre-
lations that were higher for the hypothesized scale com-
pared to competing scales. Similar to the US English ver-
sion results, baseline Cronbach’s Alpha coefficients for
the three MSQ dimensions were greater than 0.82 for all
translations. The MSQ translations were sensitive to de-
tect intervention differences after 3 months of naratrip-
tan treatment for migraines. CONCLUSIONS: The MSQ
translations have demonstrated item-level discriminant
validity, reliability, and sensitivity to detect treatment
changes in quality of life and has cross-cultural empirical
validity. The MSQ is an effective tool in assessing mi-
graine-related quality of life across different cultures.
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OBJECTIVE: To evaluate the impact of schizophrenia
versus other chronic conditions on health-related quality
of life (HRQL). METHODS: Patients who were admitted
to a psychiatric inpatient unit at one of the 100 acute
care hospitals using the CQIsm Outcomes Measurement
System were administered the SF-36 health status survey.
All patients with a discharge diagnosis of schizophrenia
who completed the SF-36 and were admitted to adult
(n  233) or geropsychiatric (n  380) inpatient units
were selected. Randomly generated observations were
drawn from general US population SF-36 data to con-
struct two general population cohorts matching the adult
and geriatric schizophrenia samples, respectively, in dis-
tribution of age and gender. Adult and geriatric schizo-
phrenic cohorts were compared to their corresponding
matched general population cohort on each of the eight
SF-36 domains. Comparisons were also made to three
disease cohorts: Hypertension, Congestive Heart Failure
(CHF), and Diabetes. Independent sample t-tests were
used to evaluate differences between the groups. RE-
SULTS: Schizophrenic patients from both adult and geri-
atric groups had significantly lower scores (P  .001) on
virtually all mental and physical HRQL domains when
compared to the general US population and to patients
with hypertension or diabetes. Both groups of schizo-
phrenics scored lower (P  .001) on mental health do-
mains when compared to CHF patients. Adult schizo-
phrenics scored higher in the physical health domains
than CHF patients (P  .05), while geriatric schizophren-
ics were similar to CHF patients in those domains. CON-
CLUSIONS: Schizophrenia’s association with lower
HRQL extends beyond mental health to physical health
status. The physical health status of schizophrenics is
more impaired than those observed in patients with dia-
betes and hypertension, and is comparable to patients
with CHF.
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